Advertisement
U.S. markets open in 4 hours 40 minutes
  • S&P Futures

    5,306.50
    -1.75 (-0.03%)
     
  • Dow Futures

    40,149.00
    +5.00 (+0.01%)
     
  • Nasdaq Futures

    18,496.25
    -7.50 (-0.04%)
     
  • Russell 2000 Futures

    2,134.30
    -4.10 (-0.19%)
     
  • Crude Oil

    81.83
    +0.48 (+0.59%)
     
  • Gold

    2,216.80
    +4.10 (+0.19%)
     
  • Silver

    24.58
    -0.18 (-0.72%)
     
  • EUR/USD

    1.0794
    -0.0035 (-0.32%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.96
    +0.18 (+1.41%)
     
  • GBP/USD

    1.2608
    -0.0030 (-0.24%)
     
  • USD/JPY

    151.3750
    +0.1290 (+0.09%)
     
  • Bitcoin USD

    70,805.89
    +1,000.77 (+1.43%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,956.46
    +24.48 (+0.31%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Mallinckrodt earnings mixed

The specialty-drug maker said EPS minus 1-time items for fiscal Q1 ended Dec. 26 more than doubled from a year ago to $1.84, beating views by 26 cents. Mallinckrodt's (MNK) sales rose 60% to $866.3 mil, about $20 mil shy of forecasts. On an earnings call with analysts, CFO Matt Harbaugh said he expects sales of 2 of the firm's leading drugs, Acthar, used to treat Addison's disease and other ailments, and pain reliever Ofirmev to be "impacted by ongoing seasonal timing" this quarter. Shares fell 1.7% to 104.93.

Advertisement